Key Takeaways The U.S. Food and Drug Administration (FDA) has rejected an industry proposal that would have reduced premarket review requirements for certain artificial intelligence (AI) -enabled medical devices, signaling that federal regulators may be unwilling to fully deregulate high-risk health AI despite broader efforts to streamline digital health oversight. The proposal, submitted by Australian […]
Key Takeaways The U.S. Food and Drug Administration (FDA) has rejected an industry proposal that would have reduced premarket review requirements for certain artificial intelligence (AI) -enabled medical devices, signaling that federal regulators may be unwilling to fully deregulate high-risk health AI despite broader efforts to streamline digital health oversight. The proposal, submitted by Australian […]
